Telaprevir‐based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|38|9|1076-1085

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.38, Iss.9, 2013-11, pp. : 1076-1085

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 8, 2015-08 ,pp. : 1309-1316

John Wiley & Sons Inc

Access to resources Recommend Favorite

Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1407-1408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of telaprevir‐based therapy for difficult‐to‐treat patients with genotype 2 chronic hepatitis C in Japan

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 7, 2015-07 ,pp. : 745-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

Factors associated with sustained virological response in 24‐week telaprevir‐based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 4, 2015-04 ,pp. : 387-396

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful treatment with telaprevir‐based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 9, 2015-09 ,pp. : 701-707

John Wiley & Sons Inc

Access to resources Recommend Favorite